ME02484B - Ljudska antitela visokog afiniteta prema ljudskom angiopoietinu-2 - Google Patents

Ljudska antitela visokog afiniteta prema ljudskom angiopoietinu-2

Info

Publication number
ME02484B
ME02484B MEP-2016-155A MEP15516A ME02484B ME 02484 B ME02484 B ME 02484B ME P15516 A MEP15516 A ME P15516A ME 02484 B ME02484 B ME 02484B
Authority
ME
Montenegro
Prior art keywords
antibody
antigen
amino acid
binding
acid sequence
Prior art date
Application number
MEP-2016-155A
Other languages
German (de)
English (en)
French (fr)
Inventor
Gavin Thurston
Christopher Daly
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42937802&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME02484(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of ME02484B publication Critical patent/ME02484B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/07—General characteristics of the apparatus having air pumping means
    • A61M2205/071—General characteristics of the apparatus having air pumping means hand operated
    • A61M2205/073—Syringe, piston type
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)

Claims (8)

1.Izolovane ljudsko antitelo ili njegov fragment koji vezuje antigen koji specifično vezuje ljudski angiopoietin-2 (hAng2) sa Ko manje od 80 pM ali ne ispoljava nikakvo vezivanje na hAng-1 kada se ispituje u ogledu površinske rezonance plazmona i koji obuhvata teški lanac CDR-1 (HCDR1) koji ima sekvencu amino kiseline sa ID BR SEK:4, HCDR-2 sa sekvencom amino kiseline ID BR SEK:6, HCDR-3 sa sekvencom amino kiseline ID BR SEK:8, laki lanaca CDR-1 (LCDR-1) sa sekvencom amino kiseline ID BR SEK:12, LCDR-2 sa sekvencom amino kiseline ID BR SEK:14, i LCDR-3 sa sekvencom amino kiseline ID BR SEK:16.
2. Izolovane antitelo ili fragment za vezivanje antigena prema patentnom zahtevu 1, pri čemu antitelo ili fragment za vezivanje antigena vezuje epitop na hAng-2 (ID BR SEK:518) koji obuhvata: (a) najmanje jednu amino kiselinu izabranu iz F-469, Y-475, i S-480; ili (b) amino kiseline F-469, Y-475, i S-480.
3. Izolovane antitelo ili fragment za vezivanje antigena prema patentom zahtevu 1 ili 2, pri čemu antitelo ili fragment za vezivanje antigena obuhvata HCVR koja ima sekvencu amino kiseline ID BR SEK: 18 i LCVR sa sekvencom amino kiseline ID BR SEK 20.
4.Izolovane antitelo ili fragment za vezivanje antigena prema jednom od patentnih zahteva 1 do 3, pri čemu antitelo ili fragment za vezivanje antigena blokira vezivanje hAng-2 na hTie-2 ali ne blokira značajno vezivanje hAng-1 na hTie-2.
5.Farmaceutsko jedinjenje koje sadrži antitelo ili fragment za vezivanje antigena prema jednom od patentnih zahteva 1 do 4 i farmaceutski prihvatljiv nosač ili razblaživač.
6.Farmaceutsko jedinjenje prema patentnom zahtevu 5 još obuhvata antagonist vaskularnog endotelijalnog faktora rasta (VEGF); pri čemu je VEGF antagonist opciono izabran iz anti-VEGF antitela, inhibitora malog molekula kinaze VEGF receptora i protein fuzije koji suzbija vaskularni endotelijalni faktor rasta (VEGF).
7. Izolovane antitelo ili fragment za vezivanje antigena prema jednom od patentnih zahteva 1 do 4 za upotrebu za lečenje pacijeta koji ima: (a) tumor; ili (b) bolest očiju povezanu sa angiogenezom.
8. Upotreba izolovanog antitela ili fragmenta za vezivanje antigena prema jednom od patentnih zahteva 1 do 4 za proizvodnju leka za upotrebu za lečenje pacijeta koji ima: (a) tumor; ili (b) bolest očiju povezanu sa angiogenezom.
MEP-2016-155A 2009-07-29 2010-07-27 Ljudska antitela visokog afiniteta prema ljudskom angiopoietinu-2 ME02484B (me)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22941809P 2009-07-29 2009-07-29
US29519410P 2010-01-15 2010-01-15
EP10737224.5A EP2459592B1 (en) 2009-07-29 2010-07-27 High affinity human antibodies to human angiopoietin-2
PCT/US2010/043295 WO2011014469A1 (en) 2009-07-29 2010-07-27 High affinity human antibodies to human angiopoietin-2

Publications (1)

Publication Number Publication Date
ME02484B true ME02484B (me) 2017-02-20

Family

ID=42937802

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2016-155A ME02484B (me) 2009-07-29 2010-07-27 Ljudska antitela visokog afiniteta prema ljudskom angiopoietinu-2

Country Status (40)

Country Link
US (4) US8987420B2 (me)
EP (1) EP2459592B1 (me)
JP (1) JP5701876B2 (me)
KR (1) KR101781786B1 (me)
CN (2) CN104258390B (me)
AR (1) AR077333A1 (me)
AU (1) AU2010276544B2 (me)
BR (1) BR112012001984B8 (me)
CA (1) CA2769334C (me)
CL (1) CL2012000229A1 (me)
CO (1) CO6491118A2 (me)
CR (1) CR20120086A (me)
CY (1) CY1117695T1 (me)
DK (1) DK2459592T3 (me)
EC (1) ECSP12011694A (me)
ES (1) ES2582405T3 (me)
HR (1) HRP20161043T1 (me)
HU (1) HUE030508T2 (me)
IL (1) IL217680A (me)
JO (1) JO3182B1 (me)
MA (1) MA33534B1 (me)
ME (1) ME02484B (me)
MX (1) MX2012001094A (me)
MY (1) MY156816A (me)
NI (1) NI201200014A (me)
NZ (1) NZ598202A (me)
PE (1) PE20121129A1 (me)
PH (1) PH12012500171A1 (me)
PL (1) PL2459592T3 (me)
PT (1) PT2459592T (me)
RS (1) RS55054B1 (me)
RU (1) RU2545399C2 (me)
SG (1) SG178114A1 (me)
SI (1) SI2459592T1 (me)
SM (1) SMT201600251B (me)
TN (1) TN2012000040A1 (me)
TW (1) TWI527591B (me)
UY (1) UY32812A (me)
WO (1) WO2011014469A1 (me)
ZA (1) ZA201200658B (me)

Families Citing this family (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
CA2527694C (en) 2003-05-30 2015-07-14 Hendricus Renerus Jacobus Mattheus Hoogenboom Fab library for the preparation of anti vegf and anti rabies virus fabs
PT1838733E (pt) * 2004-12-21 2011-12-13 Medimmune Ltd Anticorpos direccionados a angiopoietina-2 e respectivos usos
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
BRPI0821906B1 (pt) 2008-01-03 2022-06-07 The Scripps Research Institute Anticorpo isolado de comprimento total, seu uso, polinucleotideo, vetor, e célula hospedeira
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
JP5596559B2 (ja) 2008-01-28 2014-09-24 メディミューン リミテッド 安定化アンジオポエチン２抗体とその用途
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
US8133979B2 (en) 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
DK3028565T3 (da) 2009-07-08 2017-11-13 Kymab Ltd Dyremodeller og terapeutiske molekyler
US8980268B2 (en) 2009-07-29 2015-03-17 Regeneron Pharamceuticals, Inc. Methods for treating cancer by administering an anti-Ang-2 antibody
US20120189635A1 (en) 2009-07-29 2012-07-26 Regeneron Pharmaceuticals, Inc. Methods for Treating or Preventing Malaria by Administering an Antibody that Specifically Binds Angiopoietin-2 (Ang-2)
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
US20130078247A1 (en) * 2011-04-01 2013-03-28 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to dii4 and ang2
US9527925B2 (en) * 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
WO2012137993A1 (en) * 2011-04-05 2012-10-11 Neopharm Co., Ltd. Antibodies against angiopoietins 1 and 2, and their use
ES2704038T3 (es) 2011-05-24 2019-03-13 Zyngenia Inc Complejos multiespecíficos multivalentes y monovalentes y sus usos
SG10201606872TA (en) 2011-08-19 2016-10-28 Regeneron Pharma Anti-tie2 antibodies and uses thereof
CN103945689B (zh) 2011-09-19 2016-10-19 科马布有限公司 免疫球蛋白基因多样性的操纵及多抗体治疗剂
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
NZ721184A (en) 2011-09-30 2018-08-31 Dana Farber Cancer Inst Inc Therapeutic peptides
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
NZ627859A (en) * 2012-01-23 2015-09-25 Regeneron Pharma Stabilized formulations containing anti-ang2 antibodies
TWI613215B (zh) 2012-02-22 2018-02-01 再生元醫藥公司 抗－大－內皮素－１（ｂｉｇ－ｅｔ－１）抗體及其用途
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
EP2831111B1 (en) 2012-03-30 2019-03-20 Boehringer Ingelheim International GmbH Ang2-binding molecules
TWI641687B (zh) 2012-05-29 2018-11-21 美商再生元醫藥公司 生產細胞株增強子
TW201843172A (zh) 2012-06-25 2018-12-16 美商再生元醫藥公司 抗－ｅｇｆｒ抗體及其用途
WO2014009465A1 (en) 2012-07-13 2014-01-16 Roche Glycart Ag Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
ES2817925T3 (es) 2012-08-31 2021-04-08 Univ Osaka Vacuna de ADN que contiene un epítopo específico de VEGF y/o un epítopo específico de angiopoyetina-2
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
WO2014049100A1 (en) * 2012-09-28 2014-04-03 Boehringer Ingelheim International Gmbh Pharmaceutical combinations comprising dual angiopoietin-2 / dll4 binders and anti-vegf agents
CN104661678A (zh) * 2012-09-28 2015-05-27 勃林格殷格翰国际有限公司 包含双重血管生成素-2/Dll4结合物和抗VEGF-R药剂的药物组合
US20140134189A1 (en) 2012-11-13 2014-05-15 Regeneron Pharmaceuticals, Inc. Anti-prokineticin receptor (prokr) antibodies and uses thereof
GB201223053D0 (en) 2012-12-20 2013-02-06 Medical Res Council Receptor
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
WO2014144600A2 (en) 2013-03-15 2014-09-18 Viktor Roschke Multivalent and monovalent multispecific complexes and their uses
CN105142668B (zh) 2013-03-15 2018-04-27 达纳-法伯癌症研究院公司 治疗性肽
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
EP3003038B1 (en) 2013-06-07 2019-08-14 The Scripps Research Institute 2h-1,2,3-triazole derivatives as inhibitors of fibrosis
US9902767B2 (en) 2013-07-29 2018-02-27 Samsung Electronics Co., Ltd. Method of blocking vascular leakage using an anti-ANG2 antibody
KR102146845B1 (ko) 2013-07-30 2020-08-21 삼성전자주식회사 앤지오포이에틴-2에 특이적으로 결합하는 항체 및 그의 용도
KR102196450B1 (ko) 2013-09-17 2020-12-30 삼성전자주식회사 Tie2와 결합을 유도하는 항 Ang2 항체를 포함하는 항암제
SG11201602236SA (en) 2013-10-01 2016-04-28 Kymab Ltd Animal models and therapeutic molecules
WO2015058048A1 (en) 2013-10-18 2015-04-23 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of a vegf antagonist and an anti-ctla-4 antibody
SMT201900295T1 (it) 2013-11-01 2019-07-11 Regeneron Pharma Interventi a base di angiopoietina per il trattamento della malaria cerebrale
KR102206029B1 (ko) 2014-01-27 2021-01-20 삼성전자주식회사 Ang-2에 특이적으로 결합하는 항체 및 그의 용도
NZ724229A (en) 2014-03-11 2023-06-30 Regeneron Pharma Anti-egfrviii antibodies and uses thereof
EP3925973A1 (en) 2014-03-14 2021-12-22 Dana-Farber Cancer Institute, Inc. Vaccine compositions and methods for restoring nkg2d pathway function against cancers
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
SG11201609168PA (en) * 2014-05-07 2016-12-29 Medimmune Llc Methods of using anti-ang2 antibodies
AR100270A1 (es) * 2014-05-19 2016-09-21 Lilly Co Eli Anticuerpos ang2
US9994632B2 (en) 2014-05-26 2018-06-12 Samsung Electronics Co., Ltd. Humanized or affinity-matured anti Ang-2 antibody and uses thereof
EP3207059A1 (en) 2014-10-17 2017-08-23 Amgen Inc. Antibodies directed to angiopoietin-1 and angiopoietin-2 for ocular therapies
WO2016073157A1 (en) * 2014-11-06 2016-05-12 Genentech, Inc. Anti-ang2 antibodies and methods of use thereof
ES2809455T3 (es) 2014-11-17 2021-03-04 Regeneron Pharma Métodos para tratamiento tumoral usando anticuerpo biespecífico CD3xCD20
US20160144025A1 (en) * 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
JP6706023B2 (ja) 2014-12-10 2020-06-03 ザ・スクリップス・リサーチ・インスティテュート 線維症の小分子阻害剤
WO2016115218A1 (en) * 2015-01-14 2016-07-21 The California Institute For Biomedical Research Antibody drug conjugates for the treatment of immune conditions
US20160208018A1 (en) * 2015-01-16 2016-07-21 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for ror1
KR102708103B1 (ko) 2015-03-27 2024-09-20 리제너론 파아마슈티컬스, 인크. 메이탄시노이드 유도체, 이의 컨주게이트, 및 사용 방법
JOP20160154B1 (ar) 2015-07-31 2021-08-17 Regeneron Pharma أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
KR102677543B1 (ko) 2015-09-16 2024-06-24 아블렉시스, 엘엘씨 항-cd115 항체
LT3353212T (lt) 2015-09-23 2021-12-27 Regeneron Pharmaceuticals, Inc. Optimizuoti anti-cd3 bispecifiniai antikūnai ir jų naudojimas
AU2016366521A1 (en) 2015-12-11 2018-06-21 Regeneron Pharmaceuticals, Inc. Methods for reducing or preventing growth of tumors resistant to EGFR and/or ErbB3 blockade
BR112018010743B1 (pt) 2015-12-16 2024-02-15 Regeneron Pharmaceuticals, Inc Método para fabricação de um pó farmacêutico formulado, e, pó farmacêutico formulado
CN108779127B (zh) 2016-01-25 2022-07-05 里珍纳龙药品有限公司 美登素类化合物衍生物、其偶联物和使用方法
MX2018009011A (es) 2016-02-02 2018-11-19 Hutchinson Fred Cancer Res Anticuerpos anti receptor 1 transmembrana de tirosina-proteina cinasa (ror1) y usos de los mismos.
WO2017214548A1 (en) 2016-06-10 2017-12-14 Regeneron Pharmaceuticals, Inc. Anti-gitr antibodies and uses thereof
KR102565885B1 (ko) 2016-07-20 2023-08-09 유니버시티 오브 유타 리서치 파운데이션 Cd229 car t 세포 및 이의 사용 방법
CN110036032B (zh) 2016-09-23 2023-09-05 瑞泽恩制药公司 抗muc16(粘蛋白16)抗体
CA3037732A1 (en) 2016-09-23 2018-03-29 Regeneron Pharmaceuticals, Inc. Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof
WO2018089508A2 (en) * 2016-11-08 2018-05-17 Ablexis, Llc Anti-cd47 antibodies
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
EA201900312A1 (ru) 2016-11-29 2019-12-30 Регенерон Фармасьютикалз, Инк. Способы лечения пролактин-рецептор положительного рака молочной железы
WO2018114728A1 (en) 2016-12-20 2018-06-28 F. Hoffmann-La Roche Ag Combination therapy with a bispecific anti-ang2/vegf antibody and a bispecific anti-her2 antibody
EP3618876A1 (en) 2017-05-06 2020-03-11 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with aplnr antagonists and vegf inhibitors
US11434303B2 (en) 2017-06-28 2022-09-06 Bluefin Biomedicine, Inc. Anti-LY6H antibodies and antibody drug conjugates
TWI728309B (zh) * 2018-02-01 2021-05-21 大陸商南京馴鹿醫療技術有限公司 一種結合ｂｃｍａ的嵌合抗原受體（ｃａｒ）及其應用
KR102497171B1 (ko) * 2018-02-20 2023-02-08 기초과학연구원 항-안지오포이에틴-2(Ang2) 항체 및 그의 용도
EP3774866A1 (en) 2018-04-13 2021-02-17 Ludwig Institute for Cancer Research Ltd Heterodimeric inactivatable chimeric antigen receptors
KR102871690B1 (ko) 2018-04-30 2025-10-16 리제너론 파마슈티칼스 인코포레이티드 Her2 및/또는 aplp2에 결합하는 항체 및 이중특이적 항원-결합 분자 및 접합체 그리고 이들의 용도
CN112399975B (zh) 2018-06-07 2024-05-17 基础科学研究院 与Tie2结合的抗体及其用途
WO2019235856A1 (ko) 2018-06-07 2019-12-12 기초과학연구원 Tie2에 결합하는 항체 및 이의 용도
AU2020215576A1 (en) 2019-01-29 2021-07-08 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ROR1)
CN113727757A (zh) 2019-02-21 2021-11-30 瑞泽恩制药公司 使用结合met的抗-met抗体和双特异性抗原结合分子治疗眼癌的方法
JP7177284B2 (ja) * 2019-02-25 2022-11-22 ファームアブシン・インコーポレイテッド 抗ａｎｇ２抗体及びその用途
CN119954959A (zh) 2019-03-11 2025-05-09 詹森生物科技公司 抗Vβ17/抗CD123双特异性抗体
WO2020232243A2 (en) * 2019-05-14 2020-11-19 Froude Jeffrey W Antibodies to sudan and ebola virus
US20220275088A1 (en) * 2019-06-14 2022-09-01 Dana-Farber Cancer Institute, Inc. Antibodies against pd-1 and methods of use thereof
WO2020257604A1 (en) 2019-06-21 2020-12-24 Regeneron Pharmaceuticals, Inc. Use of bispecific antigen-binding molecules that bind muc16 and cd3 in combination with 4-1bb co-stimulation
MA56515A (fr) 2019-06-21 2022-04-27 Regeneron Pharma Utilisation de molécules de liaison à l'antigène bispécifiques se liant à psma et cd3 en combinaison avec une co-stimulation de 4-1bb
TWI877179B (zh) * 2019-06-27 2025-03-21 德商百靈佳殷格翰國際股份有限公司 抗-angpt2抗體
MX2022002886A (es) 2019-09-16 2022-04-06 Regeneron Pharma Proteinas de union met radiomarcadas para la obtencion de imagenes por inmuno-pet.
US11814428B2 (en) 2019-09-19 2023-11-14 Regeneron Pharmaceuticals, Inc. Anti-PTCRA antibody-drug conjugates and uses thereof
US20230141511A1 (en) 2019-12-20 2023-05-11 Ludwig Institute For Cancer Research Ltd Car-t cell therapy targeting ngcgm3
WO2021174113A1 (en) 2020-02-28 2021-09-02 Regeneron Pharmaceuticals, Inc. Bispecific antigen binding molecules that bind her2, and methods of use thereof
CA3168173A1 (en) 2020-03-06 2021-09-10 Robert Babb Anti-gitr antibodies and uses thereof
CA3183596A1 (en) * 2020-04-24 2021-10-28 Memorial Sloan-Kettering Cancer Center Chimeric antigen receptors targeting cd19 and use thereof
EP4146686A2 (en) 2020-05-08 2023-03-15 Regeneron Pharmaceuticals, Inc. Vegf traps and mini-traps and methods for treating ocular disorders and cancer
EP4178625A1 (en) 2020-07-13 2023-05-17 Regeneron Pharmaceuticals, Inc. Camptothecin analogs conjugated to a glutamine residue in a protein, and their use
EP4192864A4 (en) * 2020-08-06 2024-09-04 Stelexis Therapeutics, LLC IL-8 ANTIBODIES AND METHODS OF USE THEREOF
US20230312698A1 (en) * 2020-08-07 2023-10-05 Nanjing GenScript Biotech Co., Ltd. Antibodies against human angiopoietin-2 and uses thereof
US12448449B2 (en) 2020-09-11 2025-10-21 Janssen Biotech, Inc. Immune targeting molecules and uses thereof
CA3194752A1 (en) * 2020-09-11 2022-03-17 Janssen Biotech, Inc. Multi-specific immune targeting molecules and uses thereof
KR20230084508A (ko) 2020-09-11 2023-06-13 얀센 바이오테크 인코포레이티드 베타 사슬 매개 면역을 조절하기 위한 방법 및 조성물
NZ797493A (en) 2020-10-22 2024-05-31 Regeneron Pharma Anti-fgfr2 antibodies and methods of use thereof
CN116615257A (zh) 2020-11-10 2023-08-18 瑞泽恩制药公司 硒抗体缀合物
KR20230135627A (ko) 2021-01-25 2023-09-25 리제너론 파아마슈티컬스, 인크. 항-PDGF-b 항체 및 폐동맥 고혈압 (PAH)을 치료하기 위한 사용 방법
KR20240024061A (ko) 2021-06-22 2024-02-23 리제너론 파마슈티칼스 인코포레이티드 항-EGFRvIII 항체 약물 접합체 및 이의 용도
WO2023028004A1 (en) * 2021-08-23 2023-03-02 Avirmax, Inc. Compositions and methods for transgene expression
CN120329435A (zh) * 2021-11-26 2025-07-18 三优生物医药(上海)有限公司 抗ang2抗体及其用途
CA3241734A1 (en) 2022-01-12 2023-07-20 Amy Han Camptothecin analogs conjugated to a glutamine residue in a protein, and their use
WO2023196903A1 (en) 2022-04-06 2023-10-12 Regeneron Pharmaceuticals, Inc. Bispecific antigen-binding molecules that bind and cd3 and tumor associated antigens (taas) and uses thereof
IL316249A (en) 2022-05-02 2024-12-01 Novo Nordisk As Novel anti-angptl3 antibodies suitable for high concentration compositions and subcutaneous administration
KR20250035053A (ko) 2022-06-07 2025-03-11 리제너론 파아마슈티컬스, 인크. T 세포 활성을 조절하기 위한 다중특이적 분자 및 이의 용도
AU2023403422A1 (en) 2022-11-30 2025-07-17 Regeneron Pharmaceuticals, Inc. Tlr7 agonists and antibody-drug-conjugates thereof
CN116003591B (zh) * 2022-12-12 2023-09-19 三门峡市眼科医院 Ang-2抗体及其应用
CN120752059A (zh) 2022-12-21 2025-10-03 瑞泽恩制药公司 用于adc缀合的拓扑异构酶i抑制剂的前药及其使用方法
CN121311508A (zh) 2023-06-09 2026-01-09 徕特康(苏州)生物制药有限公司 抗her2互补性双特异抗体-药物偶联物及其制备方法和用途
CN116789813B (zh) * 2023-06-27 2024-04-26 重庆原伦生物科技有限公司 一种抗金黄色葡萄球菌α-溶血素的单克隆抗体及其应用
WO2025117727A1 (en) 2023-11-29 2025-06-05 Regeneron Pharmaceuticals, Inc. Analogs of quinoxaline/quinoline cytotoxins, linker- payloads, protein-drug conjugates, and uses thereof
WO2025186364A1 (en) 2024-03-06 2025-09-12 Jeansson Marie Angpt2-targeting antibodies for use in the treatment of fibrotic diseases, particularly kidney disease(s), disorder(s) or injury associated with kidney fibrosis

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643755A (en) 1994-10-07 1997-07-01 Regeneron Pharmaceuticals Inc. Nucleic acid encoding tie-2 ligand
US5814464A (en) 1994-10-07 1998-09-29 Regeneron Pharma Nucleic acids encoding TIE-2 ligand-2
US20030040463A1 (en) 1996-04-05 2003-02-27 Wiegand Stanley J. TIE-2 ligands, methods of making and uses thereof
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7205275B2 (en) 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
EP1631317A2 (en) * 2003-06-06 2006-03-08 Regeneron Pharmaceuticals, Inc. Use of vegf inhibitors for tumor regression
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
MX2007004247A (es) * 2004-10-19 2007-06-12 Amgen Inc Agentes de aglutinacion especifica a angiopoyetina-2.
PT1838733E (pt) 2004-12-21 2011-12-13 Medimmune Ltd Anticorpos direccionados a angiopoietina-2 e respectivos usos
US7521425B2 (en) 2005-03-03 2009-04-21 Covx Technologies Ireland Limited Anti-angiogenic compounds
WO2007033216A2 (en) 2005-09-12 2007-03-22 Beth Israel Deaconess Medical Center Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
BRPI0619853A2 (pt) 2005-12-15 2016-08-23 Astrazeneca Ab combinação, composição farmacêutica, e, métodos de antagonização da atividade biológica, de tratamento de angiogênese relacionada à doença em um mamífero e de tratamento de câncer em um mamífero
AR059066A1 (es) * 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
DK2374818T3 (da) 2006-06-02 2013-01-21 Regeneron Pharma Højaffinitetsantistoffer mod human IL-6-receptor
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
JP5596559B2 (ja) 2008-01-28 2014-09-24 メディミューン リミテッド 安定化アンジオポエチン２抗体とその用途
US8133979B2 (en) 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
TW201100543A (en) * 2009-05-27 2011-01-01 Hoffmann La Roche Tri-or tetraspecific antibodies
US8980268B2 (en) 2009-07-29 2015-03-17 Regeneron Pharamceuticals, Inc. Methods for treating cancer by administering an anti-Ang-2 antibody
US20120189635A1 (en) 2009-07-29 2012-07-26 Regeneron Pharmaceuticals, Inc. Methods for Treating or Preventing Malaria by Administering an Antibody that Specifically Binds Angiopoietin-2 (Ang-2)
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
US20160144025A1 (en) * 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases

Also Published As

Publication number Publication date
CL2012000229A1 (es) 2012-10-05
TWI527591B (zh) 2016-04-01
HK1166806A1 (zh) 2012-11-09
EP2459592B1 (en) 2016-05-18
JO3182B1 (ar) 2018-03-08
CY1117695T1 (el) 2017-05-17
MA33534B1 (fr) 2012-08-01
US9938339B2 (en) 2018-04-10
US20210101969A1 (en) 2021-04-08
US10875911B2 (en) 2020-12-29
RU2545399C2 (ru) 2015-03-27
CO6491118A2 (es) 2012-07-31
US8987420B2 (en) 2015-03-24
HUE030508T2 (en) 2017-05-29
US20180186869A1 (en) 2018-07-05
PE20121129A1 (es) 2012-09-04
PH12012500171A1 (en) 2016-03-04
ECSP12011694A (es) 2012-04-30
CA2769334C (en) 2018-06-12
CA2769334A1 (en) 2011-02-03
TW201116296A (en) 2011-05-16
PT2459592T (pt) 2016-08-17
AR077333A1 (es) 2011-08-17
HRP20161043T1 (hr) 2016-10-21
SI2459592T1 (sl) 2016-07-29
NI201200014A (es) 2012-05-29
AU2010276544B2 (en) 2014-03-27
BR112012001984B1 (pt) 2020-10-27
DK2459592T3 (en) 2016-08-29
PL2459592T3 (pl) 2016-11-30
KR101781786B1 (ko) 2017-09-26
JP2013500970A (ja) 2013-01-10
MY156816A (en) 2016-03-31
UY32812A (es) 2011-04-29
ES2582405T3 (es) 2016-09-12
US20110027286A1 (en) 2011-02-03
CN104258390B (zh) 2017-09-08
CN104258390A (zh) 2015-01-07
IL217680A (en) 2016-04-21
CN102549015A (zh) 2012-07-04
JP5701876B2 (ja) 2015-04-15
RS55054B1 (sr) 2016-12-30
US20150152177A1 (en) 2015-06-04
BR112012001984B8 (pt) 2021-05-25
CN102549015B (zh) 2014-10-15
CR20120086A (es) 2012-06-01
TN2012000040A1 (en) 2013-09-19
SG178114A1 (en) 2012-03-29
MX2012001094A (es) 2012-03-14
HK1205470A1 (en) 2015-12-18
ZA201200658B (en) 2012-10-31
WO2011014469A1 (en) 2011-02-03
AU2010276544A1 (en) 2012-03-01
SMT201600251B (it) 2016-08-31
EP2459592A1 (en) 2012-06-06
NZ598202A (en) 2013-12-20
KR20120087891A (ko) 2012-08-07
RU2012107286A (ru) 2013-09-10

Similar Documents

Publication Publication Date Title
ME02484B (me) Ljudska antitela visokog afiniteta prema ljudskom angiopoietinu-2
TWI781130B (zh) 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體
JP2019151654A (ja) ヒト抗ｇｒｅｍ１抗体
JP2018023398A5 (me)
JP2016519650A5 (me)
JP6875275B2 (ja) Ｌ１ｃａｍ（ｃｄ１７）と結合する抗体などの結合分子
JP2017500018A5 (me)
JP2017523786A5 (me)
JP2015120706A5 (me)
JP2017530722A5 (me)
US8679497B2 (en) Anti-ferroportin 1 monoclonal antibodies and uses thereof
AR069062A1 (es) Anticuerpo anti-hepcidina
JP2013514992A5 (me)
JP2013543384A5 (me)
RU2012139829A (ru) АНТИТЕЛА, НЕЙТРАЛИЗУЮЩИЕ ИНТЕГРИН ανβ8
CN114762678B (zh) 抗tigit抗体药物组合物及其用途
HRP20161096T1 (hr) Antigenski vežući proteini specifični za komponentu p serumskog amiloida
JP2008508858A (ja) マクロファージ−刺激タンパク質受容体（ｒｏｎ）の阻害
WO2016109943A1 (zh) 抗vegf抗体
JP2015511216A5 (me)
CN105820245B (zh) 抗vegf抗体
JP6231632B2 (ja) Ａｎｇ２抗体
CA2745618C (en) Anti-ferroportin 1 monoclonal antibodies and uses thereof
JP2012510814A5 (me)
JPWO2020193718A5 (me)